Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

NCT01596127 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Leukemia
Lymphoid Malignancies
Metastatic Malignant Neoplasm to the Leptomeninges

Interventions

DRUG: Intrathecal Rituximab

Sponsor

M.D. Anderson Cancer Center